Merck's anacetrapib meets LDL-C endpoint

Merck & Co. Inc. (NYSE:MRK) said once-daily anacetrapib for 76 weeks met the primary endpoint of significantly reducing LDL-C from baseline to week 24 vs. placebo in the Phase III DEFINE trial to treat coronary heart disease (36 vs. 5 mg/dL reduction, p<0.001). The cholesteryl ester transfer protein (CETP) inhibitor also met the secondary endpoint of significantly increasing mean HDL-C from baseline to week 24 vs. placebo (61 vs. 6 mg/dL increase, p<0.001). ...